AMGN

SEC source: 0001127602-13-017189 · form4.xml · nonDerivative · entry 2

BIONDI FRANK · CIK 0001032669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017189 · form4.xml · nonDerivative · entry 1

BIONDI FRANK · CIK 0001032669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · derivative · entry 11

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2022-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · derivative · entry 10

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · derivative · entry 9

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2020-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · derivative · entry 8

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2016-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · derivative · entry 7

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2015-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · nonDerivative · entry 6

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,149

F1 · price: The price reported is an average price. The prices ranged from $108.23 to $108.35 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

SEC source: 0001127602-13-017191 · form4.xml · nonDerivative · entry 5

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · nonDerivative · entry 4

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · nonDerivative · entry 3

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · nonDerivative · entry 2

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017191 · form4.xml · nonDerivative · entry 1

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-015815 · form4.xml · derivative · entry 3

Harper Sean E · CIK 0001541946 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,000 shares

Expires 2016-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-015815 · form4.xml · nonDerivative · entry 2

Harper Sean E · CIK 0001541946 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,180

F1 · price: The price reported is an average price. The prices ranged from $106.30 to $106.35 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,150 RSUs which fully vest on 4/26/2014; 25,000 RSUs which fully vest on 12/31/2014; 4,020 RSUs which vest in one installment of 1,980 on 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 200 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-015815 · form4.xml · nonDerivative · entry 1

Harper Sean E · CIK 0001541946 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-015344 · form4.xml · derivative · entry 3

de Carbonnel Francois · CIK 0001447121 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2015-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-015344 · form4.xml · nonDerivative · entry 2

de Carbonnel Francois · CIK 0001447121 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,337

F1 · balance_after: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-015344 · form4.xml · nonDerivative · entry 1

de Carbonnel Francois · CIK 0001447121 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,930

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-014777 · form4.xml · derivative · entry 8

MCNAMEE BRIAN M · CIK 0001183885 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2016-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-014777 · form4.xml · nonDerivative · entry 6

MCNAMEE BRIAN M · CIK 0001183885 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,643

F2 · price: The price reported is an average price. The prices ranged from $106.8707 to $107.1316 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

F3 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,450 RSUs which fully vest on 4/26/2014; 22,081 RSUs which fully vest on 12/31/2014; 5,025 RSUs which vest in one installment of 2,475 on 4/25/2014 and one installment of 2,550 on 4/25/2015; 4,466 RSUs which vest in three installments of 1,473, 1,474 and 1,519 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 4,439 RSUs which vest in three installments of 1,464, 1,465 and 1,510 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F4 · balance_after: These shares include 106 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014777 · form4.xml · nonDerivative · entry 5

MCNAMEE BRIAN M · CIK 0001183885 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,643

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 6

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,956

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 443 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 5

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust

Disclosed balance after: 34,851

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

SEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 4

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,382

SEC source: 0001127602-13-014767 · form4.xml · nonDerivative · entry 2

Bradway Robert A · CIK 0001396482 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,379

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/26/2014; 1,500 RSUs which fully vest on 4/26/2014; 14,070 RSUs which vest in one installment of 6,930 on 4/25/2014 and one installment of 7,140 on 4/25/2015; 20,938 RSUs which vest in three installments of 6,909, 6,910 and 7,119 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 18,693 RSUs which vest in three installments of 6,168, 6,169 and 6,356 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 487 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014769 · form4.xml · nonDerivative · entry 3

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,733

F2 · balance_after: The shares include the following RSUs granted under the Company's equity plans: 308 RSUs which fully vest on 4/26/2014; 1,149 RSUs which vest in annual installments of 566 and 583 on 4/25/2014 and 4/25/2015, respectively; 1,400 RSUs which vest in two equal installments of 462 each on 4/27/2014 and 4/27/2015 and one installment of 476 on 4/27/2016; and 942 RSUs which vest in annual installments of 310, 311 and 321 on 4/26/2015, 4/26/2016 and 4/26/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 26 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014771 · form4.xml · nonDerivative · entry 2

Harper Sean E · CIK 0001541946 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,180

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,150 RSUs which fully vest on 4/26/2014; 25,000 RSUs which fully vest on 12/31/2014; 4,020 RSUs which vest in one installment of 1,980 on 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 200 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014777 · form4.xml · nonDerivative · entry 4

MCNAMEE BRIAN M · CIK 0001183885 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,643

SEC source: 0001127602-13-014781 · form4.xml · nonDerivative · entry 2

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,442

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 132 RSUs which fully vest on 4/26/2014; 2,000 RSUs which vest in two equal annual installments of 1,000 each commencing 10/28/2013; 1,001 RSUs which vest in two installments of 493 and 508 on 4/25/2014 and 4/25/2015, respectively; 1,200 RSUs which vest in two equal installments of 396 each on 4/27/2014 and 4/27/2015 and one installment of 408 on 4/27/2016; 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively; and 2,103 RSUs which vest in three installments of 693, 694 and 716 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 82 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014783 · form4.xml · nonDerivative · entry 2

SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,537

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,450 RSUs which fully vest on 4/26/2014; 22,081 RSUs which fully vest on 12/31/2014; 7,504 RSUs which vest in one installment of 3,696 on 4/25/2014 and one installment of 3,808 on 4/25/2015; 6,141 RSUs which vest in three installments of 2,026, 2,027 and 2,088 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 5,374 RSUs which vest in two equal installments of 1,773 each on 1/28/2015 and 1/28/2016 and one installment of 1,828 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 142 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 3

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,806

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

SEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 2

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust

Disclosed balance after: 34,425

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

SEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 1

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,244

SEC source: 0001127602-13-014767 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,945

SEC source: 0001127602-13-014769 · form4.xml · nonDerivative · entry 2

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,824

SEC source: 0001127602-13-014769 · form4.xml · nonDerivative · entry 1

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,922

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/26/2015, 4/26/2016 and 4/26/2017, respectively.

SEC source: 0001127602-13-014771 · form4.xml · nonDerivative · entry 1

Harper Sean E · CIK 0001541946 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,768

SEC source: 0001127602-13-014777 · form4.xml · derivative · entry 7

MCNAMEE BRIAN M · CIK 0001183885 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2020-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-014777 · form4.xml · nonDerivative · entry 3

MCNAMEE BRIAN M · CIK 0001183885 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,354

SEC source: 0001127602-13-014777 · form4.xml · nonDerivative · entry 2

MCNAMEE BRIAN M · CIK 0001183885 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,077

F1 · price: The price reported is an average price. The prices ranged from $107.96 to $108.00 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

SEC source: 0001127602-13-014777 · form4.xml · nonDerivative · entry 1

MCNAMEE BRIAN M · CIK 0001183885 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,077

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-014781 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,491

SEC source: 0001127602-13-014783 · form4.xml · nonDerivative · entry 1

SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,281

SEC source: 0001127602-13-014787 · form4.xml · nonDerivative · entry 1

BALTIMORE DAVID · CIK 0001185858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,371

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-13-014790 · form4.xml · nonDerivative · entry 1

BIONDI FRANK · CIK 0001032669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,780

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 352 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014792 · form4.xml · nonDerivative · entry 1

COFFMAN VANCE D · CIK 0001193998 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,637

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 208 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014795 · form4.xml · nonDerivative · entry 2

de Carbonnel Francois · CIK 0001447121 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,930

F2 · balance_after: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-014795 · form4.xml · nonDerivative · entry 1

de Carbonnel Francois · CIK 0001447121 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,484

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-13-014797 · form4.xml · nonDerivative · entry 1

ECKERT ROBERT · CIK 0001194256 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,845

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.